Physician profile
David P Danowski
NPI 1982796686
$1,258.58
in general payments reported to CMS, 2019-2025
26 companies · $73.43 in 2025
The $73.43 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $225 · 2021: $111 · 2022: $190 · 2023: $292 · 2024: $14.99 · 2025: $73.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $283.36 | 2019-2025 | |
| Amgen INC. | $162.30 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $85.14 | 2019-2021 | |
| Novo Nordisk INC | $73.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $72.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $67.35 | 2019-2020 | |
| Abbott Laboratories | $47.18 | 2022-2024 | Proclaim |
| Medicure Pharma INC. | $46.36 | 2021 | |
| Abbvie INC. | $44.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.40 | 2022-2023 | |
| Exact Sciences Corporation | $39.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $32.10 | 2023 | Mounjaro |
| Scilex Pharmaceuticals INC. | $28.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.36 | 2023 | |
| Idorsia Pharmaceuticals US INC | $25.81 | 2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2020 | |
| Viiv Healthcare Company | $23.01 | 2025 | Dovato |
| Astellas Pharma US INC | $22.21 | 2023 | Veozah |
| Amag Pharmaceuticals, INC. | $16.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Janssen Biotech, INC. | $14.55 | 2019 | |
| Daiichi Sankyo INC. | $14.32 | 2020 | |
| Eisai INC. | $13.94 | 2020 | |
| Amarin Pharma, INC. | $13.76 | 2020 | |
| Boston Scientific Corporation | $11.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Danowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.